GENETIC FACTORS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS
Abstract
Amyotrophic lateral sclerosis (ALS) is a rare complex neurodegenerative disease characterized by degeneration of motor neurons in the cerebral cortex, brainstem and spinal cord. The disease mainly occurs in adults, typically between 50. and 60. years and presents with symptoms like muscular weakness, atrophy and later on paralysis which lead to death due to respiratory failure within 2-5 years from onset and remains incurable. The symptoms typically start in the muscles of arms or legs (spinal onset) or bulbary (bulbar onset). Most ALS cases are sporadic although about 5% are familiar. Genetic factors contribute to the disease in sporadic form as well as in familial form. Mutations have been found in 116 genes among which SOD1, TARDBP, FUS and C9ORF72 are represented in highest frequencies. Besides those four genes we are also describing 13 other genes involved in the disease process. Oligogenic model has been proposed for ALS that considers mutations in two or more genes in one patient. We emphasize the convergence between hereditary and sporadic form, which are clinically inseparable, and other neurodegenerative diseases that share with ALS genetic and clinical characteristics. Because about 2/3 of familial cases and only about 11% of sporadic cases are explained by mutations the research have been aimed at discovering new candidate genes using genome –wide association studies and at the epigenetic causes of the disease. We have recently completed the first representative genetic analysis of patients with ALS in Slovenia and research on methylation and microRNAs is currently in progress.
Downloads
References
Wijesekera, L.C. & Leigh, P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4, 3 (2009).
Colombrita, C. et al. RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis. Arch Ital Biol 149, 83-99 (2011).
Chio, A. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118-30 (2013).
Bocci, T. et al. Differential motor neuron impairment and axonal regeneration in sporadic and familiar amyotrophic lateral sclerosis with SOD-1 mutations: lessons from neurophysiology. Int J Mol Sci 12, 9203-15 (2011).
Kabashi, E. et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet 7, e1002214 (2011).
Logroscino, G. et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81, 385-90 (2010).
Strong, M.J., Hudson, A.J. & Alvord, W.G. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Can J Neurol Sci 18, 45-58 (1991).
Byrne, S. et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 82, 623-7 (2011).
Leblond, C.S., Kaneb, H.M., Dion, P.A. & Rouleau, G.A. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol (2014).
Aaltonen, L.A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-6 (1993).
Deng, H.X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211-5 (2011).
Siddique, T. et al. Linkage analysis in familial amyotrophic lateral sclerosis. Neurology 39, 919-25 (1989).
Rosen, D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364, 362 (1993).
Li, T.M., Alberman, E. & Swash, M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 51, 778-84 (1988).
Liscic, R.M., Grinberg, L.T., Zidar, J., Gitcho, M.A. & Cairns, N.J. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 15, 772-80 (2008).
Andersen, P.M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 7, 603-15 (2011).
Renton, A.E., Chio, A. & Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17, 17-23 (2014).
Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40, 572-4 (2008).
Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-72 (2008).
Kwiatkowski, T.J., Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-8 (2009).
Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-11 (2009).
Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-6 (2010).
Johnson, J.O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857-64 (2010).
Koppers, M. et al. Screening for rare variants in the coding region of ALS-associated genes at 9p21.2 and 19p13.3. Neurobiol Aging 34, 1518.e5-7 (2013).
DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-56 (2011).
Fecto, F. et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68, 1440-6 (2011).
Chow, C.Y. et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 84, 85-8 (2009).
Elden, A.C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-75 (2010).
Mitchell, J. et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A 107, 7556-61 (2010).
Orlacchio, A. et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 133, 591-8 (2010).
Wu, C.H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499-503 (2012).
Nishimura, A.L. et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75, 822-31 (2004).
Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29, 160-5 (2001).
Chen, Y.Z. et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74, 1128-35 (2004).
Greenway, M.J. et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38, 411-3 (2006).
Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-68 (2011).
Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65 Suppl 1, S3-9 (2009).
Andersen, P.M. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 6, 37-46 (2006).
Ticozzi, N. et al. Genetics of familial Amyotrophic lateral sclerosis. Arch Ital Biol 149, 65-82 (2011).
Felbecker, A. et al. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? J Neurol Neurosurg Psychiatry 81, 572-7 (2010).
Andersen, P.M. et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119 ( Pt 4), 1153-72 (1996).
Cudkowicz, M.E. et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41, 210-21 (1997).
Turner, M.R. et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 128, 1323-9 (2005).
Mackenzie, I.R. et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61, 427-34 (2007).
Ling, S.C. et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 107, 13318-23 (2010).
Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14, 459-68 (2011).
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-3 (2006).
Buratti, E. & Baralle, F.E. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 66, 1-34 (2009).
Chio, A. et al. Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. Arch Neurol 67, 1002-9 (2010).
Chio, A. et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain 135, 784-93 (2012).
Rutherford, N.J. et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 4, e1000193 (2008).
Wang, H.Y., Wang, I.F., Bose, J. & Shen, C.K. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83, 130-9 (2004).
Lagier-Tourenne, C. & Cleveland, D.W. Rethinking ALS: the FUS about TDP-43. Cell 136, 1001-4 (2009).
Yan, J. et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75, 807-14 (2010).
Hara, M. et al. Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation. J Neurol 259, 2237-9 (2012).
Deng, H.X. et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 67, 739-48 (2010).
Keller, B.A. et al. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol 124, 733-47 (2012).
Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11, 323-30 (2012).
Byrne, S. et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11, 232-40 (2012).
Floris, G. et al. Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype? J Neurol 259, 1749-51 (2012).
Cooper-Knock, J. et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135, 751-64 (2012).
Alzu, A. et al. Senataxin associates with replication forks to protect fork integrity across RNA-polymerase-II-transcribed genes. Cell 151, 835-46 (2012).
Williams, K.L. et al. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol Aging 33, 2527.e3-10 (2012).
Chen, H.J. et al. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285, 40266-81 (2010).
Tsuda, H. et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133, 963-77 (2008).
Daoud, H. et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 68, 739-42 (2011).
Farg, M.A. et al. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 22, 717-28 (2013).
Del Bo, R. et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 82, 1239-43 (2011).
Kachaner, D., Genin, P., Laplantine, E. & Weil, R. Toward an integrative view of Optineurin functions. Cell Cycle 11, 2808-18 (2012).
Rezaie, T. et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 295, 1077-9 (2002).
Osawa, T. et al. Optineurin in neurodegenerative diseases. Neuropathology 31, 569-74 (2011).
Albagha, O.M. et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 42, 520-4 (2010).
Koppers, M. et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 33, 837.e7-13 (2012).
Watts, G.D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36, 377-81 (2004).
Rohrer, J.D. et al. A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. J Neurol 258, 1494-6 (2011).
Meyer, H., Bug, M. & Bremer, S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 14, 117-23 (2012).
Lattante, S., Le Ber, I., Camuzat, A., Brice, A. & Kabashi, E. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. Neurobiol Aging 34, 1709.e1-2 (2013).
Chandran, J., Ding, J. & Cai, H. Alsin and the molecular pathways of amyotrophic lateral sclerosis. Mol Neurobiol 36, 224-31 (2007).
Kanekura, K. et al. Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem 279, 19247-56 (2004).
Jacquier, A. et al. Alsin/Rac1 signaling controls survival and growth of spinal motoneurons. Ann Neurol 60, 105-17 (2006).
van Es, M.A. et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 70, 964-73 (2011).
Laurin, N., Brown, J.P., Morissette, J. & Raymond, V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70, 1582-8 (2002).
Chow, C.Y. et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448, 68-72 (2007).
Su, X.W., Broach, J.R., Connor, J.R., Gerhard, G.S. & Simmons, Z. Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 49, 786-803 (2014).
Fogh, I. et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet 23, 2220-31 (2014).
Urdinguio, R.G., Sanchez-Mut, J.V. & Esteller, M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8, 1056-72 (2009).
Chestnut, B.A. et al. Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 31, 16619-36 (2011).
Morahan, J.M., Yu, B., Trent, R.J. & Pamphlett, R. A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10, 418-29 (2009).
Figueroa-Romero, C. et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One 7, e52672 (2012).
Xi, Z. et al. Hypermethylation of the CpG Island Near the GC Repeat in ALS with a C9orf72 Expansion. Am J Hum Genet (2013).
Buratti, E. et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 277, 2268-81 (2010).
Freischmidt, A. et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain (2014).
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
